What is Aperiomics?
Aperiomics operates at the intersection of big data and molecular biology, providing a unique diagnostic service that combines deep shotgun metagenomic sequencing with a proprietary database of nearly 40,000 microorganisms. By identifying every known bacterium, virus, fungus, and parasite, the company offers medical professionals a definitive tool for diagnosing complex and elusive infections. Recognized as a Life Science Innovator of the Year, Aperiomics is effectively bridging the gap between laboratory research and bedside clinical application, ensuring that patients receive accurate diagnoses and targeted treatments faster than ever before.
How much funding has Aperiomics raised?
Aperiomics has raised a total of $3.7M across 3 funding rounds:
Angel/Seed
$512K
Series A
$3M
Debt
$169K
Angel/Seed (2017): $512K with participation from Pipeline Angels
Series A (2020): $3M led by Pipeline Angels, Venture South, Atlanta Technology Angels, Propel(X), The Launch Place, and Central Texas Angel Network
Debt (2021): $169K supported by PPP
Key Investors in Aperiomics
Atlanta Technology Angels
Atlanta Technology Angels is a leading angel investor network in Georgia that supports startup and early-stage technology companies throughout the Southeast by providing financial investments, mentorship, and industry expertise.
Central Texas Angel Network
Central Texas Angel Network is a prominent angel investment firm based in Austin that connects high-net-worth individuals with promising startups to foster regional economic growth and innovation.
The Launch Place
The Launch Place offers consulting, mentoring, and training services while providing investment opportunities through its seed fund to support entrepreneurial innovation and small business growth.
What's next for Aperiomics?
With the recent influx of capital, Aperiomics is well-positioned to enhance its diagnostic infrastructure and broaden the clinical utility of its metagenomic platform. The company is expected to focus on scaling its laboratory capacity and deepening its data analytics capabilities to maintain its competitive edge in the infectious disease market. As the healthcare industry increasingly shifts toward precision medicine, Aperiomics' ability to provide comprehensive pathogen identification will likely serve as a critical component of future diagnostic protocols. Strategic efforts will likely center on expanding partnerships with major hospital systems and research institutions to solidify its market position as the standard for complex infection identification.
See full Aperiomics company page
